Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I think Rachel's analysis is pretty correct, right now. There's a ton of room for upside in her report.

Only an idiot or a fool Wall Street analyst builds or sets up their reports for major disappointment. Theyre always "better be safe than sorry"....she would look bad if she said '113 should have $15/per share value, this early in the game. There's plenty of upside in this report - other indications for Rida, 113, Ponatinib moving front line etc etc.

Her conservatism (or realistic view) will have a greater effect on stock price if she decides to improve upon her price targets when 113 becomes more front and center.